Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Darunavir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 897Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Prezista

    02 2Prezista

    03 7Prezista/Prezcobix/Rezolsta/Symtuza

    04 3Revenue share - Symtuza

    05 4Symtuza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Johnson & Johnson

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 2,184

    2019 Revenue in Millions : 2,110

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Gilead

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 488

    2019 Revenue in Millions : 379

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Johnson & Johnson

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 2,083

    2020 Revenue in Millions : 2,184

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Gilead

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 531

    2020 Revenue in Millions : 488

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Revenue share - Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Revenue share - Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Gilead

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 530

    2021 Revenue in Millions : 531

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Johnson & Johnson

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 1,943

    2021 Revenue in Millions : 2,083

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Revenue share - Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Revenue share - Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Gilead

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2023 Revenue in Millions : 529

    2022 Revenue in Millions : 530

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Darunavir

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Johnson & Johnson

    Darunavir

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2023 Revenue in Millions : 1,854

    2022 Revenue in Millions : 1,943

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Revenue share - Symtuza

    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Revenue share - Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Gilead

    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamid...

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2024 Revenue in Millions : 592

    2023 Revenue in Millions : 529

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Darunavir/Cobicistat

    arrow
    Simposio AFI
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    Simposio AFI
    Not Confirmed

    Johnson & Johnson

    Darunavir/Cobicistat

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2024 Revenue in Millions : 1,712

    2023 Revenue in Millions : 1,854

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF